Adalimumab Market

Adalimumab Market - Global Industry
Analysis, Size, Share, Growth, Trends, and
Forecast 2016 - 2024
Transparency Market Research Reports incorporated a definite
business overview and investigation inclines on "Adalimumab
Market". This report likewise incorporates more illumination
about fundamental review of the business including definitions,
requisitions and worldwide business sector industry structure.
Adalimumab, with a trade name of Humira and Exemptia, is an
anti-TNF drug used for treating rheumatoid arthritis, psoriatic
arthritis, Crohn’s disease, psoriasis and ulcerative colitis.
Adalimumab usually binds with tumor necrosis factor-alpha
(TNFα). When a TNFα binds to a TBFα receptors, it results in
an inflammatory response to autoimmune disease. Adalimumab,
by binding to a TNFα, lowers the chances of inflammatory
response.
Adalimumab, which was first approved in the U.S., is currently
being marketed in over 60 countries. Its global market is
consolidated with a handful of players trying to outsmart one
another on the basis of price. At present, most of the leading
players are focused on the development of adalimumab
biosimilars for curing rheumatoid arthritis and psoriasis. This is
palpable from the clinical trials being carried out to test the

safety and efficacy of the adalimumab biosimilars in curing the
medical conditions.
Browse Full Research Report on Adalimumab Market:
http://www.transparencymarketresearch.com/adalimumab-market.html
A report by Transparency Market Research studies the global
adalimumab market in details. It presents a qualitative analysis
of the different market trends and gauges its size and potential. It
also throws light on the different production plants, their
capacities, global production, and revenues. To do so, extensive
primary and secondary researches have been carried out.
At the forefront of driving the global adalimumab market is the
rising occurrence of arthritis worldwide. This in turn is mostly
on account of the burgeoning elderly population. In fact, most
women suffer from arthritis in old age because of loss of
calcium in the body. A sedentary lifestyle is also responsible for
growth in arthritis and another medical condition called
psoriasis. Both of them along with other factors such as rising
prevalence of Crohn’s disease and ulcerative colitis are leading
to the uptake of the product.
Adalimumab, however, is an expensive drug on account of its
biologic nature. It costs somewhere between US$2000 and
US$3000 per month. This is one factor that is serving to counter
the growth in its market.

The global adalimumab market can be segmented on the basis of
the type of disease into rheumatoid arthritis, psoriatic arthritis,
psoriasis, Crohn’s disease, and ulcerative colitis. At present, the
rheumatoid arthritis segment grosses maximum revenue and
going forward too will outshine all other segments in terms of
growth.
Geographically, the key segments of the global adalimumab
market are North America, Western Europe, Latin America, Asia
Pacific, Eastern Europe, and the Middle East and Africa. Among
them, North America and Europe are key markets. This is
because of a well-structured regulatory framework, proper
reimbursement coverage, and superior healthcare infrastructure,
particularly in the countries of Canada, the U.S., the U.K., and
Germany.
The sizeable proportion of arthritis cases owing to a sedentary
lifestyle has also led to the growth in the market in the two
continents. Asia Pacific, on the other hand, holds out a strong
promise of growth in the near future on account of a cluster of
fast-expanding developing nations in the region.

To assess the competition prevailing in the global market for
adalimumab, the report profiles major players such as Pfizer,
Amgen, Novartis AG, Boehringer Ingelheim GmbH, Mylan
N.V., and AbbVie. At present, the most prominent player in the
market is Abbott Laboratories. However, after the split of Abbott
laboratories into two companies in 2013, Humira is now the
product of AbbVie.
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze
information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.

Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com